Immatics posts ASCO anzu-cel melanoma presentation slides on PRAME-targeted TCR-T data

Immatics

Immatics

IMTX

0.00
  • Immatics released an ASCO presentation on anzu-cel (IMA203), a PRAME-targeted TCR T-cell therapy, in advanced melanoma.
  • Phase 1 melanoma efficacy set (n=33) showed confirmed ORR 56% (18/32) with median duration of response 14.6 months.
  • Median progression-free survival was 6.1 months; 12-month PFS rate was 37%.
  • Median overall survival was 16.2 months; 12-month OS was 70%.
  • Development plan includes the randomized Phase 3 SUPRAME trial (NCT06743126).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.